Author's response to reviews

Title: Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study

Authors:

Mélodie Dell'Ova (Melodie.DellOva@chu-fortdefrance.fr)
Eléonora De Maio (DeMaio.Eleonora@iuct-oncopole.fr)
Séverine Guiu (sguiu@cgl.fr)
Lise Roca (Lise.Roca@icm.unicancer.fr)
Florence Dalenc (dalenc.florence@iuct-oncopole.fr)
Anna Durigoa (Anna.DurigoAabdouh@hcuge.ch)
Frédéric Pinguet (Frederic.Pinguet@icm.unicancer.fr)
Khedidja Bekhtari (Khedidja.Bekhtari@icm.unicancer.fr)
William Jacot (William.jacot@icm.unicancer.fr)
Stéphane Pouderoux (stephane.pouderoux@icm.unicancer.fr)

Version: 5
Date: 11 August 2015

Author's response to reviews: see over
Montpellier, August 11, 2015

To the attention of Dr. Dario Palmeri
Journal Editorial Office
BMC Cancer
BioMed Central

Dear Editor,

Thank you very much for the attention, the useful comments and the interest manifested by Dr. Anna Tessari, Dr. Junji Tsurutani and yourself to our manuscript 9144236651605846 entitled “Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study” submitted for publication as a Research Article in BMC Cancer.

We were happy to view that there were no residual questions or comments from the reviewers, and we have modified the manuscript accordingly to the editorial request. You will find enclosed the point-by-point answer to the editorial request.

We hope that this modification will allow the publication of our R2 revised manuscript in BMC Cancer.

Sincerely yours,

On behalf of the authors,

William Jacot, MD, PhD
Title: Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study

Editorial request: Please include a statement in the methods to describe the body responsible for waiving the requirement for informed consent in the study and the reasoning.

Response to the Editorial Request: We included the following statement: “Considering the retrospective, non-interventional nature of this study evaluating an approved drug, no consent was deemed necessary by the clinical research review board of Montpellier cancer centre (sponsor of the study).”